Aethir, the leading provider of decentralized AI compute, announced that Predictive Oncology, a leader in AI-driven drug discovery, will amass a $344,4 million strategic compute reserve purpose built to acquire and stake ATH, the network token of Aethir.
The initiative, spearheaded by DNA Fund, a leading crypto and Web3 investment and advisory firm, and banked by BTIG is structured as a public-market vehicle and marks the first time a Nasdaq-listed company will hold and actively manage tokens of a decentralized physical infrastructure network.
The GPU shortage has emerged as one of the most significant barriers to scientific progress, constraining everything from pharmaceutical research to climate modeling.
Register for Tekedia Mini-MBA edition 18 (Sep 15 – Dec 6, 2025): registration continues.
Tekedia AI in Business Masterclass opens registrations.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab: From Technical Design to Deployment.
In oncology, training AI models to analyze massive genomic and patient datasets requires sustained access to high-performance compute, yet costs on centralized cloud providers remain prohibitively high and availability limited.
Our partnership with Aethir represents a seminal event for Predictive Oncology and we believe it creates an outstanding opportunity for the Company and our shareholders to solidify and expand our core business while embarking upon an incremental growth opportunity through our digital asset treasury strategy, commented Raymond Vennare, Chief Executive Officer and Chairman of the Board of Predictive Oncology.
DNA Holdings Venture, Inc will serve as the Company’s strategic advisor and consultant for the digital asset treasury. DNA Fund is one of the original venture capital firms in the Web3 space, led by early crypto pioneers.
The ATH Treasury directly links institutional capital with Aethir’s global GPU infrastructure, providing investors exposure to one of the fastest-growing decentralized physical infrastructure networks (DePIN).
“This is a watershed moment for the global compute problem,” said Daniel Wang, Co-founder and CEO of Aethir. “This ATH Treasury functions as a strategic compute reserve that not only validates the demand for more GPU infrastructure at the institutional level, it also provides a compliant and transparent structure for public-market investors to participate in the explosive AI compute cycle through Aethir.”
Aethir’s decentralized marketplace sources, verifies, and orchestrates enterprise-grade GPU supply, offering cost savings to centralized providers. With more than $150 million in verifiable on-chain ARR, Aethir is among the most commercially scaled projects in the DePIN category, serving enterprise clients across AI, gaming, and high-performance computing.
To date, Aethir has already delivered 1.16 billion compute hours, and over 340 million in Q3 alone, up 17.5% quarter-over-quarter. This total output is equivalent to training a model with over 7 trillion parameters in 30 days. This scale translates into real-world impact: faster AI innovation, democratized access to enterprise-grade GPUs, and 40–80% savings versus hyperscalers.
By accumulating and staking ATH, Predictive Oncology will strengthen the security and decentralization of the Aethir network while enabling institutional investors to participate in its growth without direct token custody.
Through Aethir’s unique network mechanisms, ATH can also be converted into physical GPUs, providing a direct pathway from token exposure to productive compute capacity.
About Aethir
Aethir is a decentralized cloud computing infrastructure platform delivering enterprise-grade GPU access for artificial intelligence, machine learning, and cloud gaming applications. Operating one of the largest decentralized Physical Infrastructure Networks (DePIN), Aethir connects GPU suppliers with enterprises through a global footprint of 430,000+ GPUs across 200+ deployment sites in 90+ countries.
With $150M+ in annual recurring revenue and backing from leading investors including Framework Ventures, Hashkey, Animoca Brands, and more, Aethir provides scalable, utility-driven infrastructure that lowers costs and expands access to compute worldwide.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing.
Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility.
